ClinicalTrials.Veeva

Menu

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 3

Conditions

Familial Hypercholesterolaemia

Treatments

Drug: rosuvastatin calcium

Study type

Interventional

Funder types

Industry

Identifiers

NCT01078675
D3561C00002

Details and patient eligibility

About

This study is being carried out to see if the study medication, rosuvastatin, is effective in treating familial hypercholesterolaemia in children and adolescents, and to determine the long term (over 2 years) safety, tolerability and efficacy of the study medication in these patients.

This study will also measure levels of drug in the blood and see how well it is tolerated. This is known as pharmacokinetic (PK) analysis.

At baseline only a small number of patients will participate in a single dose PK phase over 24 hours.

In order to see if this medication works, a control group of healthy siblings will help the researchers to compare certain results.

Enrollment

315 patients

Sex

All

Ages

6 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • children and adolescents (aged 6 to less than 18 years) with Familial Hypercholesterolaemia
  • Patients aged between 6 and less than 10 years of age must not be taking a statin medicine

Exclusion criteria

  • History of muscle or sensitivity reactions to any statin medicines
  • Current active liver disease or dysfunction (except a confirmed diagnosis of Gilbert's disease)

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

315 participants in 1 patient group

1
Experimental group
Treatment:
Drug: rosuvastatin calcium
Drug: rosuvastatin calcium
Drug: rosuvastatin calcium

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems